Pembrolizumab (Genetical Recombination) 100mg/4mL 1vial/case about 3560cases,and 93 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : HIRAMASTU Yuji, The Obligating Officer Director, University of Tsukuba Hospital Classification of the products to be procured : Nature and quantity of the products to be purchased : A Pembrolizumab (Genetical Recombination) 100mg/4mL 1vial/case about 3560cases B Nivolumab (Genetical Recombination) 240mg/24mL 1vial/case about 1620cases C Vutrisiran Sodium 25mg/0.5mL 1syringe/case about 20cases D Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 580cases E Efgartigimod Alfa (Genetical Recombination) 400mg/20mL 1vial/case about 650cases F Durvalumab (Genetical Recombination) 500mg/10mL 1vial/case about 720cases G Elranatamab (Genetical Recombination) 76mg/1.9mL 1vial/case about 190cases H Teprotumumab (Genetical Recombination) 500mg 1vial/case about 190cases I Epcoritamab (Genetical Recombination) 48mg/0.8mL 1vial/case about 60cases J Ipilimumab (Genetical Recombination) 50mg/10mL 1vial/case about 250cases K Amivantamab (Genetical Recombination) 350mg/7mL 1vial/case about 390cases L Risankizumab (Genetical Recombination) 150mg/1mL 1syringe/case about 330cases M Paclitaxel 100mg 1vial/case about 3230cases N Canakinumab (Genetical Recombination) 150mg/1mL 1vial/case about 70cases O Risankizumab (Genetical Recombination) 360mg/2.4mL 1kit/case about 200cases P Trastuzumab Deruxtecan (Genetical Recombination) 100mg 1vial/case about 540cases Q Lenalidomide Hydrate 5mg 40capsules/case about 320cases R Atezolizumab (Genetical Recombination) 1200mg/20mL 1vial/case about 190cases Blinatumomab (Genetical Recombination) 35㎍ 1vial/case about 270cases T Aflibercept (Genetical Recombination) 40mg 1syringe/case about 1040cases U Efgartigimod Alfa (Genetical Recombination) ・Vorhyaluronidase Alfa (Genetical Recombination) 5mg 1syringe/case about 150cases V Avelumab (Genetical Recombination) 200mg 1vial/case about 730cases W Avalglucosidase Alfa (Genetical Recombination) 100mg 1vial/case about 520cases X Sotatercept (Genetical Recombination) 45mg 1vial/case about 80cases Y Aflibercept (Genetical Recombination) 8mg 1syringe/case about 510cases Z Datopotamab Deruxtecan (Genetical Recombination) 100mg 1vial/case about 170cases AA Sacituzumab Govitecan (Genetical Recombination) 200mg 1vial/case about 330cases AB Nirsevimab (Genetical Recombination) 50mg/0.5mL 1syringe/case about 160cases AC Polyethylene Glycol Treated Human Normal Immunoglobulin 10g/100mL 1vial/case about 790cases AD Faricimab (Genetical Recombination) 6mg/0.05mL 1syringe/case about 530cases AE Letermovir 240mg 14tablets/case about 350cases AF Romiplostim (Genetical Recombination) 250㎍ 1vial/case about 1440cases AG Irinotecan Hydrochloride Hydrate 43mg/10mL 1vial/case about 530cases AH pH4-Treated Normal Human Immunoglobulin 10g/100mL 1vial/case about 520cases AI Enfortumab Vedotin (Genetical Recombination) 30mg 1vial/case about 850cases AJ Brentuximab Vedotin (Genetical Recombination) 50mg 1vial/case about 180cases AK Infliximab (Genetical Recombination) 100mg 1vial/case about 1270cases AL Denosumab (Genetical Recombination) 120mg/1mL 1syringe/case about 1210cases AM Evinacumab (Genetical Recombination) 345mg/2.3mL 1vial/case about 40cases AN Ramucirumab (Genetical Recombination) 500mg/50mL 1vial/case about 160cases AO Tarlatamab (Genetical Recombination) 10mg 1vial/case about 40cases AP Trastuzumab Emtansine (Genetical Recombination) 100mg 1vial/case about 170cases AQ Pegfilgrastim (Genetical Recombination) 3.6mg/0.36mL 1kit/case about 600cases AR pH4-Treated Normal Human Immunoglobulin 20g/200mL 1vial/case about 270cases A Tremelimumab (Genetical Recombination) 300mg/15mL 1vial/case about 10cases AT Ustekinumab (Genetical Recombination) 45mg/0.5mL 1syringe/case about 280cases AU Abatacept (Genetical Recombination) 250mg 1vial/case about 860cases AV Maribavir 200mg 28tablets/case about 30cases AW Inebilizumab (Genetical Recombination) 100mg/10mL 3vials/case about 5cases AX Cetuximab (Genetical Recombination) 100mg/20mL 1vial/case about 1750cases AY Guselkumab (Genetical Recombination) 100mg/1mL 1syringe/case about 130cases AZ Fosnetupitant Chloride Hydrochloride 235mg 5vials/case about 690cases BA Zolbetuximab (Genetical Recombination) 100mg 1vial/case about 760cases BB Obinutuzumab (Genetical Recombination) 1000mg/40mL 1vial/case about 120cases BC Leuprorelin Acetate 11.25mg 1syringe/case about 900cases BD Nirsevimab (Genetical Recombination) 100mg/1mL 1syringe/case about 50cases BE Azacitidine 100mg 1vial/case about 1530cases BF Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 460cases BG Vedolizumab (Genetical Recombination) 300mg 1vial/case about 130cases BH Lyophilized Human C1-inactivator Concentrate 50 1vial/case about 380cases BI Lanreotide Acetate 120mg 1syringe/case about 80cases BJ Mepolizumab (Genetical Recombination) 100mg/1mL 1kit/case about 210cases BK Pomalidomide 4mg 7capsules/case about 70cases BL Sotatercept (Genetical Recombination) 60mg 1vial/case about 20cases BM Leuprorelin Acetate 22.5mg 1syringe/case about 420cases BN Palonosetron Hydrochloride 0.75mL/50mL 1pack/case about 1320cases BO Trastuzumab Emtansine (Genetical Recombination) 160mg 1vial/case about 60cases BP Nivolumab (Genetical Recombination) 20mg/2mL 1vial/case about 870cases BQ Golimumab (Genetical Recombination) 50mg/0.5mL 1kit/case about 380cases BR Pomalidomide 3mg 7capsules/case about 110cases B Guselkumab (Genetical Recombination) 200mg/2mL 1kit/case about 60cases BT Selexipag 0.4mg 30tablets/case about 230cases BU Ofatumumab (Genetical Recombination) 20mg/0.4mL 1kit/case about 170cases BV Fulvestrant 250mg/5mL 2syringes/case about 380cases BW Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 1310cases BX Pegfilgrastim (Genetical Recombination) [Pegfilgrastim Biosimilar 1] 3.6mg/0.36mL 1syringe/case about 650cases BY Rituximab (Genetical Recombination) [Rituximab Biosimilar1] 500mg/50mL 1vial/case about 660cases BZ Elotuzumab (Genetical Recombination) 300mg 1vial/case about 240cases CA Panitumumab (Genetical Recombination) 400mg 1vial/case about 100cases CB Atovaquone 750mg/5mL 14packs/case about 670cases CC Anifrolumab (Genetical Recombination) 300mg/2mL 1vial/case about 230cases CD Enfortumab Vedotin (Genetical Recombination) 20mg 1vial/case about 390cases CE Tazobactam Sodium-Piperacillin Sodium for Injection 4.5g 10vials/case about 2290cases CF Tildrakizumab (Genetical Recombination) 100mg 1syringe/case about 40cases CG Panitumumab (Genetical Recombination) 100mg 1vial/case about 370cases CH Clazosentan Sodium 150mg 10vials/case about 40cases CI Macitentan 10mg 30tablets/case about 50cases CJ Doxorubicin Hydrochloride 20mg/10mL 1vial/case about 440cases CK Pomalidomide 2mg 7capsules/case about 120cases CL Bimekizumab (Genetical Recombination) 320mg/2mL 1kit/case about 60cases CM Ramucirumab (Genetical Recombination) 100mg/10mL 1vial/case about 450cases CN Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin 5000mg 1vial/case about 510cases CO Tisotumab Vedotin (Genetical Recombination) 40mg 1vial/case about 80cases CP Eptacog Alfa (Activated) (Genetical Recombination) 5mg 1kit/case about 50cases Delivery period : From July, 202 through 3 March, 202 Delivery place : The University of Tsukuba Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 4 and 4 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorshi or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A,Grade B or Grade C qualification during fiscal 202 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer, E meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 4 of the Regulation, F not be currently under a suspension of business order as instructed by The Obligating Officer. Time limit of tender : 1 : 0 June, 202 Contact point for the notice : MURASAWA Yuki, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2-1- Amakubo Tsukuba-shi 305-857 Japan, TEL 029-853-354 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-04-16